Impact of Pancreatic Stent Caliber on Post-endoscopic Retrograde Cholangiopancreatogram Pancreatitis Rates in Patients with Confirmed Sphincter of Oddi Dysfunction

Overview

Journal J Gastroenterol Hepatol

Specialty Gastroenterology

Date 2014 Mar 13

PMID 24617703

Citations 5

Authors

Jayapal Ramesh

Hwasoon Kim

Kartika Reddy

Shyam Varadarajulu

C Mel Wilcox

Affiliations

Soon will be listed here.

Abstract

Background: Despite proven clinical benefit, there are no studies that have examined the relationship between pancreatic stent caliber and its impact on PEP [post-endoscopic retrograde cholangiopancreatogram (ERCP) pancreatitis] in high-risk patients.

Aim: To study the relationship between stent caliber and PEP rates in patients with confirmed sphincter of Oddi dysfunction (SOD).

Methods: A retrospective review was conducted of ERCP's in patients with SOD from 2002 to 2012 from a prospectively maintained, Institutional Review Board approved database.

Results: A total of 243/7659 (3.2%) patients underwent 3Fr or 5Fr pancreatic stent placement following sphincterotomy for manometry-proven SOD. Of these, 133 (54.7%) underwent 3Fr stent placement, while 110 (45.3%) underwent 5Fr stent placement. There was no significant difference between the two groups in terms of baseline characteristics, demographics, and previous cholecystectomy. Cannulation and stent placement success rates were 100% in both groups. There was no significant difference in rates of PEP and overall complications, 12% versus 12.7%; P = 0.89 and 13.5% versus 15.5%; P = 0.54, between the 3Fr and 5Fr cohorts, respectively. There were more mild PEP rates recorded in 5Fr group (93% vs 56% P = 0.0549) that was not statistically significant.

Conclusions: There appears to be no relationship between stent characteristics and the risk or severity of PEP in patients with manometrically proven SOD.

Citing Articles

Evaluating the efficacy of endoscopic sphincterotomy on biliary-type sphincter of Oddi dysfunction: A retrospective clinical trial.

Ren L, Cai Z, Ran X, Yang N, Li X, Liu H World J Clin Cases. 2021; 9(32):9835-9846.

PMID: 34877322 PMC: 8610902. DOI: 10.12998/wjcc.v9.i32.9835.

Clinical course of biliary-type sphincter of Oddi dysfunction: endoscopic sphincterotomy and functional dyspepsia as affecting factors.

Miyatani H, Mashima H, Sekine M, Matsumoto S Ther Adv Gastrointest Endosc. 2019; 12:2631774519867184.

PMID: 31448369 PMC: 6693024. DOI: 10.1177/2631774519867184.

Performance measures for endoscopic retrograde cholangiopancreatography and endoscopic ultrasound: A European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative.

Domagk D, Oppong K, Aabakken L, Czako L, Gyokeres T, Manes G United European Gastroenterol J. 2018; 6(10):1448-1460.

PMID: 30574315 PMC: 6297928. DOI: 10.1177/2050640618808157.

Pancreatic Stenting Reduces Post-ERCP Pancreatitis and Biliary Sepsis in High-Risk Patients: A Randomized, Controlled Study.

Yin H, Wu H, Li Q, Wang W, Ou W, Hua-Xiang Xia H Gastroenterol Res Pract. 2016; 2016:9687052.

PMID: 27057161 PMC: 4789431. DOI: 10.1155/2016/9687052.

Sphincter of Oddi Dysfunction: Updates from the Recent Literature.

Yaghoobi M, Romagnuolo J Curr Gastroenterol Rep. 2015; 17(8):31.

PMID: 26143628 DOI: 10.1007/s11894-015-0455-z.

References

Sofuni A, Maguchi H, Itoi T, Katanuma A, Hisai H, Niido T . Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol. 2007; 5(11):1339-46. DOI: 10.1016/j.cgh.2007.07.008. View

Choudhary A, Bechtold M, Arif M, Szary N, Puli S, Othman M . Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011; 73(2):275-82. DOI: 10.1016/j.gie.2010.10.039. View

Elmunzer B, Higgins P, Saini S, Scheiman J, Parker R, Chak A . Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol. 2013; 108(3):410-5. PMC: 3947644. DOI: 10.1038/ajg.2012.442. View

Elmunzer B, Scheiman J, Lehman G, Chak A, Mosler P, Higgins P . A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012; 366(15):1414-22. PMC: 3339271. DOI: 10.1056/NEJMoa1111103. View

Lawrence C, Cotton P, Romagnuolo J, Payne K, Rawls E, Hawes R . Small prophylactic pancreatic duct stents: an assessment of spontaneous passage and stent-induced ductal abnormalities. Endoscopy. 2007; 39(12):1082-5. DOI: 10.1055/s-2007-966815. View

Cotton P, Lehman G, Vennes J, GEENEN J, Russell R, Meyers W . Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991; 37(3):383-93. DOI: 10.1016/s0016-5107(91)70740-2. View

Freeman M, Nelson D, Sherman S, Haber G, Herman M, Dorsher P . Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996; 335(13):909-18. DOI: 10.1056/NEJM199609263351301. View

Freeman M, DiSario J, Nelson D, Fennerty M, Lee J, Bjorkman D . Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54(4):425-34. DOI: 10.1067/mge.2001.117550. View

Lee T, Moon J, Choi H, Han S, Cheon Y, Cho Y . Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. Gastrointest Endosc. 2012; 76(3):578-85. DOI: 10.1016/j.gie.2012.05.001. View

10.

Stefanidis G, Karamanolis G, Viazis N, Sgouros S, Papadopoulou E, Ntatsakis K . A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc. 2003; 57(2):192-7. DOI: 10.1067/mge.2003.61. View

11.

Bockman D, Schiller W, Anderson M . Route of retrograde flow in the exocrine pancreas during ductal hypertension. Arch Surg. 1971; 103(2):321-9. DOI: 10.1001/archsurg.1971.01350080237038. View

12.

Akbar A, Abu Dayyeh B, Baron T, Wang Z, Altayar O, Murad M . Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013; 11(7):778-83. DOI: 10.1016/j.cgh.2012.12.043. View

13.

Cheon Y, Cho K, Watkins J, McHenry L, Fogel E, Sherman S . Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc. 2007; 65(3):385-93. DOI: 10.1016/j.gie.2006.10.021. View

14.

Cotton P, Garrow D, Gallagher J, Romagnuolo J . Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009; 70(1):80-8. DOI: 10.1016/j.gie.2008.10.039. View

15.

Freeman M . Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2007; 5(11):1354-65. DOI: 10.1016/j.cgh.2007.09.007. View

16.

Zolotarevsky E, Fehmi S, Anderson M, Schoenfeld P, Elmunzer B, Kwon R . Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy. 2011; 43(4):325-30. PMC: 3514442. DOI: 10.1055/s-0030-1256305. View

17.

Fogel E, Eversman D, Jamidar P, Sherman S, Lehman G . Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy. 2002; 34(4):280-5. DOI: 10.1055/s-2002-23629. View

18.

Varadarajulu S, Wilcox C . Endoscopic management of sphincter of Oddi dysfunction in children. J Pediatr Gastroenterol Nutr. 2006; 42(5):526-30. DOI: 10.1097/01.mpg.0000221891.21254.a2. View

19.

Cheng C, Sherman S, Watkins J, Barnett J, Freeman M, Geenen J . Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006; 101(1):139-47. DOI: 10.1111/j.1572-0241.2006.00380.x. View

20.

Chahal P, Tarnasky P, Petersen B, Topazian M, Levy M, Gostout C . Short 5Fr vs long 3Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2009; 7(8):834-9. DOI: 10.1016/j.cgh.2009.05.002. View